Aquestive Therapeutics Inc [AQST] stock prices are up 14.80% to $4.50 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AQST shares have gain 10.02% over the last week, with a monthly amount drifted -15.73%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aquestive Therapeutics Inc [NASDAQ: AQST] stock has seen the most recent analyst activity on April 11, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $10. Previously, Raymond James started tracking the stock with Outperform rating on March 28, 2024, and set its price target to $7. H.C. Wainwright started tracking the stock assigning a Buy rating. Lake Street initiated its recommendation with a Buy and recommended $14 as its price target on January 03, 2019. RBC Capital Mkts started tracking with a Outperform rating for this stock on August 20, 2018, and assigned it a price target of $23. In a note dated August 20, 2018, JMP Securities initiated an Mkt Outperform rating and provided a target price of $29 on this stock.
The stock price of Aquestive Therapeutics Inc [AQST] has been fluctuating between $1.15 and $6.23 over the past year. Currently, Wall Street analysts expect the stock to reach $10.33 within the next 12 months. Aquestive Therapeutics Inc [NASDAQ: AQST] shares were valued at $4.50 at the most recent close of the market. An investor can expect a potential return of 129.56% based on the average AQST price forecast.
Analyzing the AQST fundamentals
The Aquestive Therapeutics Inc [NASDAQ:AQST] reported sales of 50.58M for trailing twelve months, representing a surge of 23.63%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.02%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is -0.03 and Total Capital is -0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.12 points at the first support level, and at 3.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.70, and for the 2nd resistance point, it is at 4.89.
Ratios To Look Out For
It’s worth pointing out that Aquestive Therapeutics Inc [NASDAQ:AQST]’s Current Ratio is 2.24. Also, the Quick Ratio is 1.87, while the Cash Ratio stands at 1.3. Considering the valuation of this stock, the price to sales ratio is 8.00.
Transactions by insiders
Recent insider trading involved Schobel Alexander Mark, Chief Innovation/Tech Officer, that happened on Mar 15 ’24 when 50000.0 shares were sold. Chief Innovation/Tech Officer, Schobel Alexander Mark completed a deal on Mar 08 ’24 to sell 25000.0 shares.
